References
- Al-Bayati MA, Xie Y, Mohr FC, Margolin SB, Giri SN. (2002). Effect of pirfenidone against vanadate-induced kidney fibrosis in rats. Biochem Pharmacol 64:517–525.
- Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. (1995). Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261–270.
- Chen XP, Han XM, Jiang CH, Huang SL, Liu ZQ, Zhu B, Zhou G, Zhou HH. (2002). Phenotype distribution and gender-related differences of CYP2E1 activity in a Chinese population. Xenobiotica 32:1053–1062.
- Cifuentes A, Valencia J, Sanz E, Sánchez MJ, Rodríguez-Delgado MA. (1997). Separation and quantitation of debrisoquine and 4-hydroxydebrisoquine in human urine by capillary electrophoresis and high-performance liquid chromatography. J Chromatogr A 778:389–396.
- Fuhr U, Rost KL, Engelhardt R, Sachs M, Liermann D, Belloc C, Beaune P, Janezic S, Grant D, Meyer UA, Staib AH. (1996). Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 6:159–176.
- Giri SN, Wang Q, Xie Y, Lango J, Morin D, Margolin SB, Buckpitt AR. (2002). Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration. Biopharm Drug Dispos 23:203–211.
- Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN. (1995). Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med 125:779–785.
- Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. (1997). Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 25:853–862.
- Landi MT, Sinha R, Lang NP, Kadlubar FF. (1999). Human cytochrome P4501A2. IARC Sci Publ 148:173–195.
- Lasker JM, Wester MR, Aramsombatdee E, Raucy JL. (1998). Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys 353:16–28.
- Lehmann B, Boulieu R. (1995). Determination of midazolam and its unconjugated 1-hydroxy metabolite in human plasma by high-performance liquid chromatography. J Chromatogr B, Biomed Appl 674:138–142.
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275.
- Maurel P. (1998). Drug metabolizing enzymes. Curr Opin Crit Care, 4, 213–18.
- Newton DJ, Wang RW, Lu AY. (1995). Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154–158.
- Omura T, Sato R. (1964). The carbon monoxide-binding pigment of liver microsomes. i. evidence for its hemoprotein nature. J Biol Chem 239:2370–2378.
- Ou-Yang DS, Huang SL, Xie HG, Wang CY, Zhou HH. (1998). Use of caffeine as a probe for rapid determination of cytochrome P-450 CYP1A2 activity in humans. Zhongguo Yao Li Xue Bao 19:44–46.
- Raghu G, Johnson WC, Lockhart D, Mageto Y. (1999). Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 159:1061–1069.
- Rendic S, Di Carlo FJ. (1997). Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413–580.
- Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423.
- von Bahr C, Groth CG, Jansson H, Lundgren G, Lind M, Glaumann H. (1980). Drug metabolism in human liver in vitro: establishment of a human liver bank. Clin Pharmacol Ther 27:711–725.
- von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI. (1998). In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 55:113–122.
- Gahl WA, Brantly M, Troendle J, Avila NA, Padua A, Montalvo C, Cardona H, Calis KA, Gochuico B. (2002). Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab 76:234–242.